CD47 and cancer: Indeed, the augmented anti-cancer efficacy of RT conferred by Sirpα-deficient macrophages was unmatched by therapeutic combinations with anti-PD-L1 checkpoint inhibitors, CD47-blockade, and/or antitumor antibodies.